I thought it would be interesting to see how the Laninamivir trial results has impacted the stock price of Daiichi Sankyo.
Interestingly, since the announcement the market cap has risen by around AUD1.8bn, a huge number! So who's correct? Aussie investors which priced in a LOWER share price since the release (total market cam ~360m) or Japanese investors pricing in an extra $1.8bn cap into Daiichi Sankyo?
http://advance.quote.nomura.co.jp/meigara/nomura2/quote.cgi?F=english/edchart&QCODE=4568&MKTN=T
This rise has been attributed to Laninamivir:
"Pharma stock Daiichi Sankyo Co. extended its winning streak to seven days Tuesday, buoyed by hopes for the drugmaker's new anti-influenza agent CS-8958, or laninamivir. On Monday afternoon, the drugmaker said that clinical trials have shown the new treatment to be more effective than Tamiflu, a popular product currently in the market, when administered to children aged nine and under."
http://www.ibtimes.com/articles/20090810/asian-markets-mostly-trading-flat-amid-cautious-mood.htm
I haven't checked the numbers, just looked at the chart and assumed 709m shares, exchange rate of 78... i don't have daily prices for DS unfortunately. Perhaps someone can reply with the correct figure if they have some time.
- Forums
- ASX - By Stock
- laninamivir increased ds market cap by ~1.8bn
I thought it would be interesting to see how the Laninamivir...
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online